Pathogenesis of myeloma bone disease

被引:278
|
作者
Roodman, G. D. [1 ]
机构
[1] Univ Pittsburgh, Vet Affairs Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, Sch Med, Pittsburgh, PA 15240 USA
关键词
multiple myeloma; osteoclast; osteoblast; bone disease; KAPPA-B LIGAND; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR-NECROSIS-FACTOR; MULTIPLE-MYELOMA; RECEPTOR ACTIVATOR; IN-VIVO; INHIBITS OSTEOCLASTOGENESIS; OSTEOBLAST DIFFERENTIATION; MARROW MICROENVIRONMENT; PROTEASOME INHIBITOR;
D O I
10.1038/leu.2008.336
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Bone disease in multiple myeloma (MM) is characterized by lytic bone lesions, which can cause severe bone pain, pathologic fractures and hypercalcemia. However, the lytic bone disease in MM differs from that in other cancer patients who have lytic bone metastases. Although increased osteoclastic bone destruction is involved in MM and other tumors involving bone, in contrast to other tumors, once the MM tumor burden exceeds 50% in a local area, osteoblast activity is either suppressed or absent. 1 The basis for this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been a topic of intensive investigation over the last several years and will be reviewed in this article.
引用
收藏
页码:435 / 441
页数:7
相关论文
共 50 条
  • [41] Bone disease in multiple myeloma
    Hjertner, Oyvind
    Standal, Therese
    Borset, Magne
    Sundan, Anders
    Waage, Anders
    MEDICAL ONCOLOGY, 2006, 23 (04) : 431 - 441
  • [42] Treatment for myeloma bone disease
    Yeh, Howard S.
    Berenson, James R.
    CLINICAL CANCER RESEARCH, 2006, 12 (20) : 6279S - 6284S
  • [43] Pathogenesis of Paget Disease of Bone
    Ralston, Stuart H.
    Layfield, Rob
    CALCIFIED TISSUE INTERNATIONAL, 2012, 91 (02) : 97 - 113
  • [44] Pathogenesis of Paget Disease of Bone
    Stuart H. Ralston
    Rob Layfield
    Calcified Tissue International, 2012, 91 : 97 - 113
  • [45] Multiple Myeloma: Molecular Pathogenesis and Disease Evolution
    Heider, Michael
    Nickel, Katharina
    Hoegner, Marion
    Bassermann, Florian
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (12) : 672 - 680
  • [46] Role of intensive therapy in myeloma and myeloma bone disease
    Barlogie, B
    Walker, R
    Rasmussen, E
    Anaissie, E
    Tricot, G
    Shaughnessy, J
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 : P14 - P14
  • [47] Bone Disease From Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: Pathogenesis, Interventions, and Future Opportunities
    Minter, Alex R.
    Simpson, Haley
    Weiss, Brendan M.
    Landgren, Ola
    SEMINARS IN HEMATOLOGY, 2011, 48 (01) : 55 - 65
  • [48] BONE BIOMARKERS ARE USEFUL IN MONITORING MYELOMA BONE DISEASE AND AS EARLY PREDICTOR FOR RELAPSE DISEASE IN MULTIPLE MYELOMA
    Ting, K.
    Hameed, A.
    Brady, J.
    Carke, C.
    Justine, M.
    Dowling, P.
    Clynes, M.
    O'Gorman, P.
    HAEMATOLOGICA, 2013, 98 : 334 - 335
  • [49] Multiple myeloma pathogenesis: the role of JUNB in bone marrow angiogenesis
    Malvestiti, S.
    Fan, F.
    Bashari, H.
    Vallet, S.
    Sattler, M.
    Bakiri, L.
    Seckinger, A.
    Hose, D.
    Goldschmidt, H.
    Zoernig, I.
    Pecherstorfer, M.
    Wagner, E. F.
    Tassone, P.
    Jaeger, D.
    Podar, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 206 - +
  • [50] Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis
    Fan, Fengjuan
    Malvestiti, Stefano
    Shen, Yujia
    Morelli, Eugenio
    Mishima, Yuji
    Seckinger, Anja
    Hose, Dirk
    Bakiri, Latifa
    Vallet, Sonia
    Sattler, Martin
    Roccaro, Aldo M.
    Goldschmidt, Hartmut
    Percherstorfer, Martin
    Sun, Chunyan
    Hu, Yu
    Wagner, Erwin F.
    Tassone, Piefrancesco
    Ghobrial, Irene M.
    Jaeger, Dirk
    Podar, Klaus
    BLOOD, 2019, 134